Evoke Pharma Inc (EVOK)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Net product sales | 3,752,142 | 3,080,158 | 2,654,186 | |
| Selling, general and administrative | 5,134,902 | 4,297,505 | 3,824,142 | |
| Research and development | 8,413 | 42,783 | 11,677 | |
| Cost of goods sold | 167,679 | 41,613 | 104,024 | |
| Total operating expenses | 5,310,994 | 4,381,901 | 3,939,843 | |
| Loss from operations | -1,558,852 | -1,301,743 | -1,285,657 | |
| Interest income | 112,534 | 118,853 | 99,294 | |
| Interest expense | 124,658 | 123,288 | 126,027 | |
| Total other expense | -12,124 | -4,435 | -26,733 | |
| Net loss | -1,570,976 | -1,306,178 | -1,312,390 | |
| Earnings per share basic | -0.62 | -0.51 | -0.94 | |
| Earnings per share diluted | -0.62 | -0.51 | -0.94 | |
| Weighted average number of diluted shares outstanding | 2,553,174 | 2,548,684 | 1,399,882 | |
| Weighted average number of shares outstanding basic | 2,553,174 | 2,548,684 | 1,399,882 | |